+

WO2004071396A3 - Diagnostics et therapeutique pour des maladies associees au recepteur 2 de l'hormone parathyroide (pthr2) - Google Patents

Diagnostics et therapeutique pour des maladies associees au recepteur 2 de l'hormone parathyroide (pthr2) Download PDF

Info

Publication number
WO2004071396A3
WO2004071396A3 PCT/EP2004/000990 EP2004000990W WO2004071396A3 WO 2004071396 A3 WO2004071396 A3 WO 2004071396A3 EP 2004000990 W EP2004000990 W EP 2004000990W WO 2004071396 A3 WO2004071396 A3 WO 2004071396A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
pthr2
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2004/000990
Other languages
English (en)
Other versions
WO2004071396A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2004071396A2 publication Critical patent/WO2004071396A2/fr
Publication of WO2004071396A3 publication Critical patent/WO2004071396A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un PTHR2 humain associé aux troubles du système nerveux périphérique et central, à des inflammations, à des maladies urologiques, au cancer, à des maladies métaboliques, à des maladies respiratoires, à des maladies endocrinologiques et à des maladies hématologiques. L'invention concerne également des essais pour l'identification de composés utiles dans le traitement ou la prévention de troubles du système nerveux périphérique et central, d'inflammations, de maladies urologiques, du cancer, de maladies métaboliques, de maladies respiratoires, de maladies endocrinologiques et de maladies hématologiques. L'invention concerne encore des composés qui se lient et/ou activent ou inhibent l'activité de PTHR2 ainsi que des compositions pharmaceutiques contenant de tels composés.
PCT/EP2004/000990 2003-02-17 2004-02-04 Diagnostics et therapeutique pour des maladies associees au recepteur 2 de l'hormone parathyroide (pthr2) WO2004071396A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003537.2 2003-02-17
EP03003537 2003-02-17

Publications (2)

Publication Number Publication Date
WO2004071396A2 WO2004071396A2 (fr) 2004-08-26
WO2004071396A3 true WO2004071396A3 (fr) 2004-10-28

Family

ID=32864941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000990 WO2004071396A2 (fr) 2003-02-17 2004-02-04 Diagnostics et therapeutique pour des maladies associees au recepteur 2 de l'hormone parathyroide (pthr2)

Country Status (1)

Country Link
WO (1) WO2004071396A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057139A2 (fr) * 1998-05-05 1999-11-11 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Composes se liant selectivement au recepteur pth2
WO2000077042A2 (fr) * 1999-06-15 2000-12-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands des recepteurs pth2 et pth1
WO2001009328A1 (fr) * 1999-08-03 2001-02-08 Millennium Pharmaceuticals, Inc. Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere
WO2001077172A2 (fr) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Recepteurs connus couples a la proteine g non endogenes a activation constitutive
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057139A2 (fr) * 1998-05-05 1999-11-11 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Composes se liant selectivement au recepteur pth2
WO2000077042A2 (fr) * 1999-06-15 2000-12-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands des recepteurs pth2 et pth1
WO2001009328A1 (fr) * 1999-08-03 2001-02-08 Millennium Pharmaceuticals, Inc. Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere
WO2001077172A2 (fr) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Recepteurs connus couples a la proteine g non endogenes a activation constitutive
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARTER P H J]PPNER H GARDELLA T J: "Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: Receptor subtype-selective agonists, antagonists and photochemical cross-linking agents", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 140, no. 11, 1999, pages 4972 - 4981, XP002956874, ISSN: 0013-7227 *
HOARE S R J BONNER T I USDIN T B: "Comparison of rat and human parathyroid hormone 2 (PTH2) receptor activation: PTH is a low potency partial agonist at the rat PTH2 receptor", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 140, no. 10, October 1999 (1999-10-01), pages 4419 - 4425, XP002956875, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
WO2004071396A2 (fr) 2004-08-26

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004097421A3 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
WO2003081258A3 (fr) Diagnostics et elements therapeutiques pour maladies associees au recepteur secretagogue de l'hormone de croissance (ghs)
WO2003093816A3 (fr) Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005106491A3 (fr) Diagnostic et traitement therapeutique de maladies associees a la kinase 1 regulee par serum/glucocorticoide (sgk1)
WO2004082570A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2)
WO2004071396A3 (fr) Diagnostics et therapeutique pour des maladies associees au recepteur 2 de l'hormone parathyroide (pthr2)
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2004073587A3 (fr) Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1)
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2005101001A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c)
WO2004086047A3 (fr) Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2004071393A3 (fr) Diagnostic et therapeutique pour des maladies associees au recepteur peptide 1 de type glucagon
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2004097034A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 4 transmembranaire humaine (tmprss4)
WO2003100434A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 2 de l'arginine vasopressine (avpr2)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005075990A3 (fr) Diagnostics et therapeutiques pour maladies associees au recepteur nucleaire humain nr4a2 (nr4a2)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载